The average price point forecasted by analysts for Esperion Therapeutics Inc. (ESPR) is $8.25, which is $7.0 above the current market price. The public float for ESPR is 112.56M, and currently, short sellers hold a 16.19% ratio of that floaft. The average trading volume of ESPR on November 20, 2023 was 3.93M shares.

ESPR) stock’s latest price update

Esperion Therapeutics Inc. (NASDAQ: ESPR)’s stock price has increased by 5.05 compared to its previous closing price of 1.19. However, the company has seen a 32.22% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-12 that Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US and EU in 2024 could significantly broaden bempedoic acid’s market reach, with a potential addressable market of 70 million patients. An ongoing legal dispute with Daiichi presents a potential upside for Esperion, with the possibility of a favorable ruling that could de-risk a $300M milestone payment.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


ESPR’s Market Performance

Esperion Therapeutics Inc. (ESPR) has seen a 32.22% rise in stock performance for the week, with a 52.27% gain in the past month and a -12.58% plunge in the past quarter. The volatility ratio for the week is 13.32%, and the volatility levels for the past 30 days are at 11.45% for ESPR. The simple moving average for the last 20 days is 34.73% for ESPR stock, with a simple moving average of -34.77% for the last 200 days.

ESPR Trading at 26.67% from the 50-Day Moving Average

After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.91% of loss for the given period.

Volatility was left at 11.45%, however, over the last 30 days, the volatility rate increased by 13.32%, as shares surge +55.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.14% lower at present.

During the last 5 trading sessions, ESPR rose by +30.62%, which changed the moving average for the period of 200-days by -79.07% in comparison to the 20-day moving average, which settled at $0.9498. In addition, Esperion Therapeutics Inc. saw -79.93% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 742 shares at the price of $1.25 back on Sep 20. After this action, Warren Eric now owns 68,318 shares of Esperion Therapeutics Inc., valued at $924 using the latest closing price.

Warren Eric, the Chief Commercial Officer of Esperion Therapeutics Inc., sale 243 shares at $1.41 during a trade that took place back on Aug 18, which means that Warren Eric is holding 69,060 shares at $344 based on the most recent closing price.

Stock Fundamentals for ESPR

Current profitability levels for the company are sitting at:

The net margin for Esperion Therapeutics Inc. stands at -309.58. The total capital return value is set at -71.65, while invested capital returns managed to touch -100.88.

When we switch over and look at the enterprise to sales, we see a ratio of 4.60, with the company’s debt to enterprise value settled at 0.67. The receivables turnover for the company is 2.66 and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.67.


In a nutshell, Esperion Therapeutics Inc. (ESPR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.